Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series.

Cramer JP, Jelinek T, Paulke-Korinek M, Reisinger EC, Dieckmann S, Alberer M, Bühler S, Bosse D, Meyer S, Fragapane E, Costantini M, Pellegrini M, Lattanzi M, Dovali C.

J Travel Med. 2016 Mar 19;23(3). pii: taw011. doi: 10.1093/jtm/taw011. Print 2016 Mar.

PMID:
26994987
2.

Five year follow-up after primary vaccination against tick-borne encephalitis in children.

Wittermann C, Izu A, Petri E, Gniel D, Fragapane E.

Vaccine. 2015 Apr 8;33(15):1824-9. doi: 10.1016/j.vaccine.2015.02.038. Epub 2015 Feb 26.

PMID:
25728316
3.

A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59®: adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults.

Herbinger KH, von Sonnenburg F, Nothdurft HD, Perona P, Borkowski A, Fragapane E, Nicolay U, Clemens R.

Hum Vaccin Immunother. 2014;10(1):92-9. doi: 10.4161/hv.26495. Epub 2013 Sep 20.

4.

Ex vivo analysis of human memory B lymphocytes specific for A and B influenza hemagglutinin by polychromatic flow-cytometry.

Bardelli M, Alleri L, Angiolini F, Buricchi F, Tavarini S, Sammicheli C, Nuti S, Degl'Innocenti E, Isnardi I, Fragapane E, Del Giudice G, Castellino F, Galli G.

PLoS One. 2013 Aug 15;8(8):e70620. doi: 10.1371/journal.pone.0070620. eCollection 2013.

5.

Human circulating influenza-CD4+ ICOS1+IL-21+ T cells expand after vaccination, exert helper function, and predict antibody responses.

Spensieri F, Borgogni E, Zedda L, Bardelli M, Buricchi F, Volpini G, Fragapane E, Tavarini S, Finco O, Rappuoli R, Del Giudice G, Galli G, Castellino F.

Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14330-5. doi: 10.1073/pnas.1311998110. Epub 2013 Aug 12.

6.

A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects.

Czajka H, Unal S, Ulusoy S, Usluer G, Strus A, Sennaroglu E, Guzik J, Topeli Iskit A, Dargiewicz A, Musial D, Caylan R, Dziduch J, Eskioglu E, Hasiec B, Cwinarowiczliwa E, Belli R, Abdel-Messih IA, Beygo J, Fragapane E.

J Prev Med Hyg. 2012 Sep;53(3):136-42. Erratum in: J Prev Med Hyg. 2012 Dec;53(4):220. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.

PMID:
23362618
7.

Impact of preexisting memory to seasonal A/H1N1 influenza virus on the immune response following vaccination against avian A/H5N1 virus.

Buricchi F, Bardelli M, Malzone C, Capecchi B, Nicolay U, Fragapane E, Castellino F, Del Giudice G, Galli G, Finco O.

Eur J Immunol. 2013 Mar;43(3):641-8. doi: 10.1002/eji.201242563. Epub 2013 Jan 24.

8.

Aflunov®: a vaccine tailored for pre-pandemic and pandemic approaches against influenza.

Del Giudice G, Fragapane E, Della Cioppa G, Rappuoli R.

Expert Opin Biol Ther. 2013 Jan;13(1):121-35. doi: 10.1517/14712598.2013.748030. Epub 2012 Nov 29. Review.

PMID:
23189937
9.

Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects.

Bihari I, Pánczél G, Kovacs J, Beygo J, Fragapane E.

Clin Vaccine Immunol. 2012 Dec;19(12):1943-8. doi: 10.1128/CVI.00373-12. Epub 2012 Oct 17.

10.

Immunogenicity, safety, and tolerability of two trivalent subunit inactivated influenza vaccines: a phase III, observer-blind, randomized, controlled multicenter study.

Tregnaghi MW, Stamboulian D, Vanadía PC, Tregnaghi JP, Calvari M, Fragapane E, Casula D, Pellegrini M, Groth N.

Viral Immunol. 2012 Jun;25(3):216-25. doi: 10.1089/vim.2011.0063.

PMID:
22691101
11.

Phase III, randomized controlled trial to evaluate lot consistency of a trivalent subunit egg-based influenza vaccine in adults.

Rivera L, Mazara S, Vargas M, Fragapane E, Casula D, Groth N.

Vaccine. 2012 Jul 27;30(35):5285-92. doi: 10.1016/j.vaccine.2012.05.021. Epub 2012 May 31.

PMID:
22659448
12.
13.

A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly.

Fragapane E, Gasparini R, Schioppa F, Laghi-Pasini F, Montomoli E, Banzhoff A.

Clin Vaccine Immunol. 2010 Nov;17(11):1817-9. doi: 10.1128/CVI.00461-09. Epub 2010 Sep 1.

14.

MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis.

Banzhoff A, Pellegrini M, Del Giudice G, Fragapane E, Groth N, Podda A.

Influenza Other Respir Viruses. 2008 Nov;2(6):243-9. doi: 10.1111/j.1750-2659.2008.00059.x. Review.

15.

Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults.

Durando P, Fenoglio D, Boschini A, Ansaldi F, Icardi G, Sticchi L, Renzoni A, Fabbri P, Ferrera A, Parodi A, Bruzzone B, Gabutti G, Podda A, Del Giudice G, Fragapane E, Indiveri F, Crovari P, Gasparini R.

Clin Vaccine Immunol. 2008 Feb;15(2):253-9. Epub 2007 Nov 14.

16.

Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases.

Baldo V, Baldovin T, Floreani A, Fragapane E, Trivello R; Family Medicine Group.

J Clin Immunol. 2007 Sep;27(5):542-7. Epub 2007 May 21.

PMID:
17514499
17.

Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene.

Del Giudice G, Fragapane E, Bugarini R, Hora M, Henriksson T, Palla E, O'hagan D, Donnelly J, Rappuoli R, Podda A.

Clin Vaccine Immunol. 2006 Sep;13(9):1010-3.

18.

Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects.

Gasparini R, Pozzi T, Montomoli E, Fragapane E, Senatore F, Minutello M, Podda A.

Eur J Epidemiol. 2001;17(2):135-40.

PMID:
11599686
19.

Prevalence of diphtheria toxin antibodies in human sera from a cross-section of the Italian population.

Bergamini M, Comodo N, Gasparini R, Gabutti G, Fabrizi P, Severini R, Ajello F, Bonanni P, Castagnari L, Cocchioni M, Della Pietra P, Fragapane E, Grilli A, Liberatore S, Lo Nostro A, Moiraghi-Ruggenini A, Pellegrini MG, Pozzi T, Tarsitani G, Zotti C, Crovari P.

Vaccine. 1999 Jan 21;17(3):286-90.

PMID:
9987165
20.

Immunity to diphtheria in Siena.

Gasparini R, Pozzi T, Fragapane E, Severini R, Cellesi C, Fabrizi P, Provvedi A, Bergamini M.

Epidemiol Infect. 1997 Oct;119(2):203-8.

Supplemental Content

Loading ...
Support Center